discoveri
heavi
chainonli
antibodi
serum
camel
first
report
hamer
et
al
open
way
new
tool
box
divers
therapeut
applic
sera
camelid
camel
dromedari
llama
contain
convent
antibodi
isotyp
surprisingli
also
antibodi
lack
light
chain
compon
well
first
constant
domain
heavi
chain
isotyp
epitopebind
unit
socal
heavi
chainonli
antibodi
thu
consist
singl
variabl
domain
call
singledomain
antibodi
vhh
despit
small
size
kda
singl
domain
bind
unit
exquisit
affin
antigenbind
specif
similar
variabl
domain
convent
antibodi
vhh
consist
four
constant
framework
region
separ
three
hypervari
complementar
determin
loop
distinct
featur
vhh
presenc
hydrophil
surfac
expos
patch
like
evolv
compens
loss
light
chain
bind
addit
loop
vhh
often
fold
back
site
normal
interact
variabl
light
chain
moreov
vhh
variabl
length
typic
somewhat
longer
convent
antibodi
compens
higher
flexibl
otherwis
entrop
unfavor
bind
target
antigen
loop
often
form
disulfid
bond
small
size
singl
domain
buildup
presenc
hydrophil
amino
acid
go
togeth
typic
high
solubl
physic
stabil
vhh
result
protein
withstand
rel
harsh
formul
environ
excel
tissu
penetr
capac
format
multipl
way
effici
produc
low
cost
microorgan
surprisingli
given
appeal
properti
vhh
direct
number
virus
includ
influenza
virus
human
immunodefici
human
respiratori
syncyti
viru
rsv
isol
immun
synthet
vhh
librari
immun
librari
gener
base
peripher
blood
lymphocyt
isol
camelid
immun
complet
viru
viral
antigen
interest
primeboost
strategi
howev
vhh
reason
target
specif
also
isol
librari
gener
camelid
immun
target
viral
antigen
interest
synthet
vhh
librari
requir
experiment
anim
handl
librari
built
base
well
character
vhh
conserv
fr
retain
amino
acid
cdr
alter
satur
site
specif
mutagenesi
immun
librari
often
first
choic
isol
high
affin
vhh
natur
somat
antibodi
matur
creat
enorm
divers
antigenspecif
vhh
usual
isol
phage
yeast
ribosom
display
numer
virusneutr
vhh
describ
differ
step
viral
life
cycl
perturb
figur
exampl
vhh
prevent
viru
entri
block
receptor
bind
describ
influenza
target
hemagglutinin
ha
protein
hiv
target
middl
east
respiratori
syndrom
coronavirus
mer
cov
target
spike
protein
furthermor
vhh
arrest
rsv
fusion
protein
f
prefus
state
could
prevent
viru
entri
inhibit
membran
fusion
viru
host
cell
express
within
target
cell
vhh
often
refer
intrabodi
affect
exampl
viral
replic
nuclear
transport
viral
ribonucleoprotein
vrnp
shown
antiinfluenza
nucleoprotein
vhh
vhh
hiv
rev
protein
could
inhibit
nuclear
export
viral
mrna
apart
direct
antivir
activ
vhh
may
vhh
format
serv
target
moieti
bring
effector
function
toxin
antivir
drug
antibodyderiv
fc
domain
site
viral
infect
vhh
format
also
use
increas
halflif
affin
target
deliv
vhh
certain
compart
last
vhh
format
explor
develop
new
diagnost
tool
infecti
diseas
focu
multitud
format
appli
vhh
target
human
virus
tabl
singl
vhh
molecul
molecular
weight
approxim
kda
ten
time
smaller
convent
igg
antibodi
size
around
kda
inject
monomer
dimer
even
trimer
vhh
thu
rapidli
clear
circul
free
glomerular
filtrat
kidney
molecular
weight
cutoff
kda
rapid
remov
within
coupl
hour
inject
compar
week
convent
antibodi
often
limit
therapeut
efficaci
vhh
result
vhh
administ
infus
repeat
inject
even
restrict
locoregion
treatment
import
note
strict
correl
molecular
weight
molecul
halflif
exampl
genet
fusion
vhh
fc
domain
capac
interact
neonat
fc
receptor
fcrn
restor
increas
retent
vhh
even
expect
base
size
clear
case
halflif
vhh
need
extend
order
obtain
maxim
therapeut
efficaci
prolong
halflif
maintain
therapeut
threshold
longer
time
also
reduc
frequenc
drug
administr
significantli
benefit
patient
four
major
strategi
discuss
use
improv
pharmacokinet
vhh
gener
goal
limit
renal
elimin
recov
alreadi
avail
circul
vhh
molecul
first
frequent
employ
method
aim
increas
size
hydrodynam
radiu
vhh
avoid
glomerular
filtrat
simpl
way
accomplish
coupl
two
three
homolog
heterolog
vhh
via
specif
linker
howev
even
bival
construct
still
rapidli
clear
complex
method
oligomer
vhh
use
platform
technolog
allow
display
vhh
differ
format
describ
includ
socal
fenobodi
fan
et
al
display
platform
base
ferritin
spheric
iron
storag
protein
exampl
broadli
reactiv
antiinfluenza
vhh
anchor
result
vhhdisplay
fenobodi
target
affin
time
higher
monoval
counterpart
well
higher
halflif
vhh
also
chemic
modifi
order
increas
molecular
weight
chemic
modif
exampl
polyethylen
glycol
peg
group
may
also
protect
vhh
proteas
coval
attach
peg
procedur
often
refer
pegyl
approv
food
drug
administr
therapeut
protein
wide
use
prolong
halflif
biopharmaceut
interestingli
pegyl
vhh
neutral
highli
contagi
foot
mouth
diseas
viru
fmdv
picornaviru
increas
halflif
guinea
pig
also
significantli
increas
neutral
capac
addit
peg
molecul
molecular
mass
higher
kda
might
result
accumul
vhh
interest
tissu
therebi
reduc
target
access
next
chemic
modif
biotherapeut
also
result
reduc
bioactiv
affin
molecul
interest
furthermor
safeti
concern
associ
use
pegyl
protein
drug
peg
metabol
human
bodi
pegyl
biopharmaceut
taken
cell
lead
vacuol
combin
rel
high
cost
pegyl
molecul
abovement
cautionari
note
use
pegyl
extend
drug
halflif
rous
interest
compani
explor
safer
econom
altern
use
recombin
peg
mimet
genet
fuse
molecul
interest
one
exampl
altern
review
second
approach
tri
avoid
renal
clearanc
biopharmaceut
base
interest
observ
neg
charg
small
protein
remain
longer
circul
neutral
protein
like
due
repuls
neg
charg
molecul
neg
charg
glomerular
basement
membran
kidney
sever
way
add
neg
charg
protein
includ
addit
sialic
acid
polym
polysialyl
hydroxyeth
starch
hesyl
fusion
highli
sialyat
beta
carboxytermin
peptid
ctp
amino
acidresidu
found
human
chorion
gonadotropin
hcg
hormon
unlik
peg
natur
occur
polym
biodegrad
would
interest
modifi
vhh
neg
charg
polym
assess
outcom
term
halflif
vivo
efficaci
anoth
strategi
extend
halflif
vhh
coupl
vhh
longliv
serum
protein
build
block
target
longliv
protein
long
serum
halflif
serum
albumin
exampl
result
abil
escap
catabol
cellular
uptak
acid
endosom
compart
albumin
abl
bind
fcrn
recycl
bound
albumin
back
ph
neutral
extracellular
milieu
human
serum
albumin
termin
elimin
halflif
day
human
prefer
target
choic
direct
indirect
fusion
vhh
studi
hoefman
et
al
report
signific
increas
halflif
differ
mono
di
trimer
vhh
construct
fuse
albumin
bind
vhh
follow
singl
intraven
bolu
administr
halflif
extend
construct
could
still
detect
serum
day
mice
day
monkey
construct
fuse
irrelev
vhh
longer
detect
within
one
day
administr
terryn
et
al
also
genet
fuse
homoand
heterobival
vhh
target
glycoprotein
g
rabi
viru
albuminspecif
vhh
order
extend
halflif
albuminbind
capac
construct
result
approxim
higher
system
exposur
improv
median
surviv
time
rabi
viru
challeng
treat
mice
sever
week
compar
bival
construct
respect
import
mention
halflif
albumin
rodent
small
mammal
around
day
markedli
shorter
sever
day
week
observ
differ
immunoglobulin
ig
addit
advantag
fusion
bind
albumin
fact
might
help
target
vhh
specif
site
bodi
sinc
report
albumin
accumul
tumor
inflam
tissu
halflif
ig
rang
one
almost
four
week
depend
subclass
isotyp
therefor
iggbas
fusion
construct
also
wide
use
extend
halflif
therapeut
protein
includ
vhh
exampl
socal
genet
fusion
fmdvneutral
vhh
vhh
target
porcin
igg
construct
harmsen
et
al
bind
porcin
igg
possibl
increas
halflif
observ
prophylact
intramuscular
treatment
also
reduc
viral
load
shed
unfortun
fmdv
challengeassoci
clinic
sign
transmiss
diseas
could
prevent
molecul
model
use
altogeth
data
obtain
harmsen
et
al
show
prolong
exposur
time
imper
immunotherapi
efficaci
addit
fine
tune
paramet
also
import
fourth
approach
extend
vhh
halflif
fuse
vhh
interest
fc
region
fcbind
moieti
igg
molecul
extend
halflif
chimer
antibodi
construct
demonstr
raj
et
al
ctermin
extend
vhh
neutral
merscov
fc
part
human
protein
resembl
heavi
chainonli
antibodi
show
enhanc
merscov
neutral
capac
protect
correl
sustain
high
level
vhhfc
circul
parallel
zhao
et
al
show
stabl
bind
merscov
neutral
vhh
fuse
human
fc
recombin
merscov
spike
protein
serum
collect
day
postinject
contrast
monoval
format
merscov
vhh
bind
could
detect
day
case
improv
protect
merscov
infect
fc
fuse
construct
attribut
increas
size
dimer
thu
extend
halflif
effect
bind
fcrn
report
studi
instanc
affin
antivir
vhh
pick
initi
select
step
still
need
improv
order
enhanc
broaden
neutral
capac
addit
increas
affin
might
import
reduc
viral
escap
end
one
could
chang
affin
vhh
target
antigen
vitro
affin
matur
secondgener
librari
construct
introduc
random
mutat
select
part
vhh
scaffold
usual
cdr
exampl
affin
parathyroid
hormon
pth
deriv
peptidespecif
vhh
isol
phage
display
librari
gener
naiv
llama
could
enhanc
select
vhh
deriv
librari
vhh
mutat
randomli
introduc
codon
anoth
way
increas
affin
introduc
avid
effect
join
two
vhh
multival
construct
use
flexibl
linker
sever
studi
demonstr
benefici
outcom
type
vhh
format
improv
affin
avid
effect
addit
increas
bind
avid
format
could
also
increas
neutral
activ
increas
structur
restrict
site
differ
protom
protein
link
vhh
construct
three
type
multival
vhh
format
distinguish
monospecif
fusion
two
ident
vhh
recogn
epitop
join
bispecif
fusion
two
vhh
recogn
differ
epitop
connect
format
vhh
fuse
protein
moieti
tendenc
dimer
multimer
strength
introduc
avid
affin
vhh
target
antigen
extens
examin
hultberg
et
al
studi
multival
construct
gener
rsv
f
fusion
protein
influenza
ha
rabi
g
protein
remark
link
two
ident
antif
vhh
increas
rsv
neutral
capac
approxim
addit
bival
trival
antiha
bival
anti
vesicular
stomat
viru
vsv
g
vhh
significantli
higher
neutral
potenc
monoval
counterpart
flexibl
gs
linker
rang
amino
acid
residu
test
optim
linker
length
need
achiev
avid
effect
like
depend
avail
space
viral
epitop
need
empir
test
vhh
combin
trival
antiinfluenza
ha
vhh
amino
acid
residu
linker
lower
neutral
activ
compar
construct
amino
acid
residu
linker
contrast
bival
rsv
f
specif
vhh
either
amino
acidlink
equal
potent
neutral
rsv
hulsik
et
al
develop
vhh
vhh
direct
membran
proxim
extern
region
mper
epitop
hiv
viral
fusion
protein
bival
construct
two
vhh
molecul
link
gs
linker
higher
bind
efficaci
compar
monomer
vhh
increas
affin
associ
increas
breadth
neutral
variou
strain
resist
monoval
vhh
could
neutral
addit
use
gs
linker
cardoso
et
al
use
llama
hing
flexibl
linker
fuse
two
ident
antiinfluenza
neuraminidas
na
vhh
similar
abovement
studi
antivir
potenc
bival
format
significantli
enhanc
anoth
exampl
vhh
acquir
increas
viru
neutral
breadth
increas
avid
report
influenza
virus
target
bival
version
vhh
gener
fuse
two
ident
vhh
direct
stem
ha
pandem
viru
use
amino
acid
gs
linker
similar
neutral
potenc
virus
monoval
howev
neutral
diverg
viru
strain
increas
bival
format
even
gain
abil
neutral
strain
author
propos
increas
antivir
breadth
result
slower
rate
rescu
low
affin
interact
similarli
broader
antivir
spectrum
observ
bival
format
vhh
direct
site
site
surfac
envelop
glycoprotein
signific
improv
neutral
potenc
multival
protein
term
observ
compar
parent
monoval
vhh
apart
vitro
increas
antivir
potenc
impact
avid
effect
also
observ
vivo
experi
et
al
show
vhh
bival
format
protect
mice
lethal
viru
challeng
least
effect
monoval
counterpart
base
lung
viral
titer
doserespons
comparison
experi
similarli
intranas
administr
bival
rsv
fspecif
vhh
bival
rabi
gspecif
vhh
show
increas
vivo
potenc
compar
monoval
counterpart
furthermor
homotrimer
vhh
high
bind
affin
rsv
f
potent
rsv
neutral
activ
current
evalu
phase
iib
clinic
trial
treatment
diseas
caus
rsv
infect
infant
interestingli
vitro
experi
trival
vhh
outperform
palivizumab
monoclon
human
antibodi
direct
epitop
rsv
f
protein
current
use
prophylact
antirsv
treatment
could
possibl
explain
enhanc
access
epitop
due
small
size
vhh
flexibl
gs
linker
compar
antibodi
hing
presenc
third
fbind
modul
explor
impact
avid
effect
emerg
escap
mutant
vitro
palomo
et
al
serial
passag
rsv
long
strain
presenc
monoval
trival
vhh
reveal
much
difficult
viru
escap
trival
compar
monoval
vhh
addit
trival
format
still
abl
neutral
rsv
escap
mutant
anoth
way
overcom
viral
escap
broaden
neutral
activ
use
bispecif
format
compris
two
vhh
target
differ
viral
epitop
hultberg
et
al
demonstr
crossneutr
significantli
improv
rsv
rabiesneutr
bispecif
format
compar
correspond
monoval
bival
monospecif
construct
gener
singl
molecul
headtotail
fusion
gs
linker
bispecif
target
recognit
key
improv
mere
mix
monoval
vhh
equimolar
ratio
hardli
increas
potenc
compar
individu
monoval
vhh
interestingli
posit
vhh
rel
bispecif
fusion
construct
influenc
potenc
influenc
also
observ
bispecif
vhh
direct
site
induc
site
bispecif
construct
vhh
ntermin
vhh
ctermin
posit
outperform
construct
vhh
opposit
posit
final
also
possibl
increas
affin
neutral
potenc
fuse
vhh
protein
moieti
tendenc
oligomer
exampl
tillib
et
al
fuse
trimer
variant
leucin
zipper
domain
deriv
yeast
transcript
factor
cterminu
antiinfluenza
ha
vhh
format
vhh
adopt
trimer
conform
approxim
time
activ
compar
unformat
vhh
likewis
boruah
et
al
use
anoth
type
coiledcoil
form
domain
gener
multival
vhh
even
possibl
gener
call
combodi
construct
vhh
fuse
coiledcoil
domain
deriv
human
cartilag
oligomer
matrix
protein
result
pentaval
vhh
format
compar
monoval
format
combodi
abl
neutral
higher
input
rabi
viru
pseudotyp
vitro
sinc
pentamer
build
block
combodi
human
origin
reduc
risk
becom
immunogen
upon
administr
human
compar
yeast
leucin
zipper
domain
anoth
oligomer
approach
develop
socal
fenobodi
describ
attract
way
gener
bival
vhh
fusion
fc
domain
convent
antibodi
igg
iga
exampl
cardoso
et
al
fuse
influenza
naspecif
vhh
mous
fc
domain
fc
format
vhh
show
higher
na
inhibit
approxim
higher
vitro
antivir
activ
compar
monoval
vhh
import
advantag
vhhfc
fusion
construct
introduct
fc
receptordepend
effector
function
complement
activ
possibl
engag
effector
function
antibodydepend
phagocytosi
activ
discuss
next
paragraph
next
direct
viru
neutral
convent
antibodi
also
employ
fcmediat
effector
function
control
viral
infect
effector
function
includ
antibodydepend
cellmedi
cytotox
adcc
antibodydepend
cellmedi
phagocytosi
adcp
complementdepend
cytotox
cdc
mechan
elimin
infect
cell
virion
import
effector
function
increasingli
recogn
antibodi
mediat
protect
infect
eg
influenza
viru
rsv
zika
viru
hiv
vhh
lack
fc
region
therefor
facilit
effector
function
howev
thank
singl
domain
natur
vhh
readili
equip
variou
effector
function
molecular
biochem
engin
vhh
link
fc
region
also
toxin
liposom
ligand
bind
scaffold
fc
region
differ
human
mous
antibodi
subclass
genet
fuse
vhh
target
differ
virus
outlin
fc
fusion
greatli
increas
serum
halflif
enhanc
target
antigen
bind
avid
effect
tabl
antivir
vhhfc
import
acquir
fcassoci
effector
function
investig
eg
vitro
assay
vhh
target
second
extracellular
loop
chemokin
receptor
prevent
entri
replic
strain
use
coreceptor
fuse
domain
human
antibodi
strongli
increas
potenc
vhh
bind
surfac
cell
prevent
infect
addit
enabl
adcc
target
cell
evidenc
activ
induct
natur
killer
nk
cell
degranul
select
kill
target
cell
nk
could
also
mediat
complementdepend
kill
cell
express
high
level
whether
acquir
effector
function
also
contribut
protect
vitro
vivo
remain
determin
potenti
impact
vhhfc
effector
function
vivo
well
illustr
vhh
target
rotaviru
protein
influenza
na
ha
protein
antirotaviru
protein
vhh
direct
conserv
rotaviru
inner
capsid
protein
wherea
convent
antibodi
direct
outer
capsid
protein
typic
mediat
serotyp
specif
neutral
antibodi
direct
gener
fail
remark
nonneutr
specif
iga
monoclon
antibodi
protect
mice
rotaviru
infect
given
system
deliv
lumin
side
intestin
deliv
intracellularli
protein
lipofect
antibodi
abl
block
rotaviru
transcript
interf
rotaviru
capsid
structur
nonneutr
iga
could
control
rotaviru
replic
vivo
transcytosi
sharp
contrast
convent
antibodi
vhh
target
potent
neutral
rotavirus
divers
serotyp
control
rotaviru
infect
neonat
mice
fed
oral
recent
report
clinic
trial
demonstr
therapeut
oral
administr
yeast
produc
safe
effect
reduc
diarrhea
male
infant
sever
rotavirusassoci
diarrhea
tri
improv
protect
capac
vhh
fuse
mous
fc
region
evalu
vivo
compar
monoval
vhh
oral
prophylact
treatment
far
effect
reduc
preval
durat
sever
diarrhea
rotavirusinfect
neonat
mice
pup
observ
fab
fragment
much
less
effect
illustr
capac
fcarp
due
bival
natur
suggest
import
fcassoci
effector
function
role
fc
effector
function
demonstr
reduc
protect
capac
variant
contrast
interact
fcrn
intracellular
antibodi
receptor
expect
unaffect
interact
receptor
suggest
next
direct
neutral
fcarp
may
addit
mediat
intracellular
neutral
intern
via
fcrn
bind
cell
intracellular
antibodi
receptor
recogn
complex
target
proteasom
degrad
initi
antivir
innat
immun
respons
still
potent
vhh
fc
effector
function
might
also
contribut
protect
provid
potenti
contribut
fc
effector
function
vhhfc
mediat
protect
also
observ
nonneutr
fcvhh
direct
na
protein
isol
na
bind
vhh
block
na
activ
consequ
also
vitro
viral
replic
bival
format
vhh
na
inhibit
activ
gener
headtotail
fc
fusion
least
potent
monoval
counterpart
inhibit
na
activ
least
plaqu
size
reduct
assay
contrast
fc
fusion
format
bind
na
fail
inhibit
na
activ
viral
replic
vitro
howev
despit
lack
detect
antivir
activ
vitro
prophylact
treatment
mice
fc
fusion
format
monoval
vhh
could
partial
protect
otherwis
lethal
influenza
viru
infect
suggest
protect
activ
depend
fc
effector
function
direct
evid
import
fc
effector
function
recent
report
multival
vhhfc
protein
provid
broad
protect
influenza
b
viru
infect
studi
experiment
molecul
compris
headtotail
fusion
four
differ
vhh
link
human
igg
fc
region
separ
vhh
potent
neutral
group
influenza
virus
group
influenza
virus
victoria
lineag
influenza
b
yamagata
lineag
influenza
b
virus
prophylact
treatment
mice
could
protect
infect
divers
influenza
b
virus
challeng
dose
lethal
control
treat
anim
leucin
alanin
mutat
fc
region
lala
human
mous
variant
abrog
interact
receptor
therebi
elimin
adcc
adcp
cdc
activ
substanti
decreas
protect
capac
clearli
demonstr
import
fc
effector
function
antivir
activ
vhhfc
protein
next
fusion
fc
region
also
approach
use
arm
vhh
fc
effector
function
exampl
sun
et
al
fuse
convent
antibodi
vhh
target
coreceptor
bind
site
expos
upon
bind
antibodyvhh
chimera
effici
block
infect
cell
vhh
fc
region
antibodyvhh
construct
could
also
engag
effector
function
howev
investig
gray
et
al
link
vhh
dinitrophenyl
dnp
recruit
antidnp
antibodi
omnipres
human
sera
dnpfuse
vhh
could
engag
peripher
blood
mononuclear
cell
pbmc
kill
express
target
cell
adcc
altern
vhh
specif
target
human
iii
fuse
tumor
antigenspecif
vhh
could
kill
tumor
cell
induc
adcc
reduc
tumor
growth
mice
xenograft
tumor
cell
human
pbmc
last
approach
might
interest
arm
virusspecif
vhh
variou
fc
effector
function
next
exploit
host
fc
effector
function
vhh
also
equip
foreign
effector
function
vhh
target
herp
simplex
type
glycoprotein
bind
cell
express
protein
fail
neutral
infect
vitro
howev
fuse
cytotox
domain
pseudomona
aeruginosa
exotoxin
vhh
effici
kill
infect
cell
reduc
viral
replic
fusion
vhh
toxin
explor
strategi
respect
control
tcell
acut
lymphoblast
leukemia
multipl
myeloma
vhhbase
immunotoxin
could
repres
valuabl
approach
control
latent
viral
infect
caus
virusspecif
vhh
could
also
use
bring
cargo
compris
eg
liposom
load
antivir
drug
select
infect
cell
shield
toxic
drug
liposom
may
reduc
system
toxic
increas
efficaci
deliv
antivir
site
infect
wang
et
al
conjug
neutral
specif
vhh
liposom
wherea
noncoval
conjug
interfer
neutral
vhh
coval
conjug
liposom
although
revers
transcriptas
inhibitor
dapivirin
encapsul
liposom
higher
antivir
activ
free
dapivirin
conjug
dapivirin
load
liposom
increas
antivir
activ
optim
could
potenti
lead
pronounc
antivir
therapi
case
vhh
effect
need
certain
organ
cell
type
cell
compart
multipl
format
option
avail
specif
target
deliv
vhh
one
region
eg
linkag
antibodi
peptid
provid
posttransl
modif
situ
express
bacteri
vector
deliveri
vhh
organ
system
gastrointestin
tract
easili
achiev
use
bacteri
vector
approach
use
develop
therapi
rotaviru
infect
direct
oral
administr
antirotaviru
vhh
reduc
rotavirusinduc
diarrhea
clinic
studi
deliv
vhh
use
bacteri
vehicl
could
result
enhanc
sustain
protect
vhh
express
bacteri
vector
accomplish
direct
vhh
surfac
bacteria
secret
vhh
lactobacillu
paracasei
engin
two
way
result
either
express
mono
bival
anoth
rotavirusneutr
vhh
bacteri
surfac
product
monoval
secret
andor
surfac
display
protein
first
strategi
led
lactobacilli
could
reduc
rate
diarrhea
mice
prophylact
therapeut
set
slightli
improv
efficaci
bival
vhh
compar
monoval
vhhexpress
bacterium
use
second
combin
strategi
viru
could
captur
vhh
surfac
lactobacillu
wherea
secret
vhh
could
bind
distinct
epitop
efficaci
strategi
yet
test
vivo
anoth
group
made
use
probiot
strain
lactobacillu
rhamnosu
gg
modifi
display
surfac
display
lactobacillu
strain
intrins
antirotaviru
activ
result
amelior
clinic
paramet
upon
rotaviru
challeng
infect
mice
compar
origin
strain
none
modifi
bacteria
test
yet
clinic
studi
studi
somewhat
complic
regulatori
perspect
concern
use
genet
modifi
microorgan
also
use
bacteri
vector
restrict
organ
microbiom
gut
skin
nasal
caviti
vagina
organ
target
link
vhh
interest
vhh
specif
bind
organspecif
marker
protein
enrich
vhh
organ
choic
upon
system
administr
next
target
complet
organ
advantag
target
one
cell
type
case
antihiv
antibodi
format
consist
hivneutr
ibalizumab
imab
monoclon
antibodi
link
two
copi
broadli
hivneutr
vhh
imab
specif
receptor
hiv
link
vhh
antibodi
concentr
broadli
neutral
vhh
enhanc
site
infect
result
synergist
antivir
effect
compar
mixtur
separ
imab
vhh
last
vhh
also
target
specif
cell
compart
exert
function
liu
et
al
exampl
describ
strategi
target
hivneutr
vhh
toward
lipid
raft
cell
membran
entri
viral
releas
hiv
reli
lipid
raft
host
cell
membran
target
antihiv
vhh
site
infect
could
therefor
increas
effect
vhh
possibl
use
glycosylphosphatidylinositol
gpi
signal
hydrophob
moieti
guid
protein
lipid
raft
plasma
membran
gene
construct
made
link
code
inform
hiv
gpi
signal
sequenc
transduct
cell
construct
result
broad
potent
neutral
transduct
construct
code
secret
neutral
subtyp
limit
techniqu
gpivhh
need
produc
cell
function
could
achiev
modifi
patientderiv
cell
lentivir
vector
carri
gpivhh
sequenc
transfus
cell
back
patient
anoth
exampl
gpilink
vhh
describ
tiwari
et
al
develop
antirsv
strategi
base
mrna
code
gpilink
rsvneutral
vhh
describ
rossey
et
al
strategi
vitro
produc
vhhcode
mrna
directli
deliv
lung
result
transient
express
therapeut
vhh
respiratori
epitheli
cell
includ
gpi
anchor
construct
vhh
direct
epitheli
cell
surfac
site
rsv
entri
compar
construct
rsvvhh
secret
gpianchor
rsvneutral
vhh
could
reduc
rsv
infect
mice
even
administ
seven
day
infect
mainli
due
enhanc
lung
retent
thank
gpi
anchor
viral
target
may
locat
insid
infect
cell
thu
hard
reach
antivir
vhh
problem
howev
overcom
link
vhh
cellpenetr
peptid
penetratin
approach
appli
develop
antihepat
c
viru
hcv
vhh
sever
intracellular
viral
protein
consid
target
viral
rnadepend
rna
polymeras
helicasentpas
multifunct
hcv
protein
vitro
penetratinlink
vhh
direct
target
could
suppress
hcv
replic
vhh
test
yet
vivo
sturdi
natur
small
size
eas
product
make
singl
domain
antibodi
well
suit
build
block
use
applic
diagnost
howev
context
virustarget
vhh
came
across
exampl
literatur
exploit
vhh
detect
viral
antigen
one
explan
pauciti
studi
probabl
tremend
sensit
nucleic
acidbas
detect
method
diagnosi
viral
infect
howev
term
speed
clear
rapid
antibodybas
detect
method
outcompet
dna
rnabas
detect
method
virus
known
manifest
antigen
divers
structur
protein
vhhbase
detect
method
challeng
unless
broadli
reactiv
yet
highli
specif
vhh
avail
human
norovirus
exampl
antigen
variabl
virus
differ
genotyp
classifi
two
main
genogroup
furthermor
noroviru
outbreak
spread
astonish
speed
warrant
avail
rapid
robust
diagnosi
method
could
help
contain
outbreak
soon
possibl
first
patient
fall
ill
one
vhh
recogn
epitop
lower
region
protrud
domain
noroviru
capsid
conserv
among
genotyp
ii
norovirus
develop
tool
rapid
diagnost
noroviru
capsidbind
vhh
modifi
biotin
conjug
gold
modif
allow
use
rapid
later
flow
immunoassay
interestingli
compar
commerci
avail
elisa
analysi
human
stool
sampl
vhh
later
flow
immunoassay
higher
specif
compar
although
one
five
case
miss
vhh
set
sensit
later
flow
immunoassay
compar
commerci
elisa
use
multipl
vhh
ideal
also
recogn
genotyp
norovirus
would
like
contribut
higher
sensit
influenza
virus
likewis
display
high
antigen
variabl
also
rapid
detect
method
base
singl
domain
antibodi
would
requir
broadli
reactiv
sandwich
type
elisa
propos
base
two
singl
domain
antibodi
deriv
camel
immun
inactiv
semipurifi
viru
singl
domain
antibodi
specif
hemagglutinin
viru
sandwich
elisa
one
singl
domain
antibodi
tether
magnet
bead
second
one
coupl
report
enzym
semipurifi
viru
detect
minim
concentr
ngml
unclear
report
singl
domain
antibodi
pair
abl
recogn
multipl
strain
second
vhhbase
tool
context
viru
develop
group
david
rowland
group
long
stand
design
hepat
b
corebas
viruslik
particl
vlp
express
robust
express
system
base
e
coli
plant
recent
group
report
socal
tandem
fusion
hepat
b
core
vlp
assembl
method
singledomain
antibodi
direct
green
fluoresc
protein
gfp
insert
major
immunodomin
region
second
hepat
b
core
moieti
tandem
construct
recombin
vlp
produc
purifi
could
captur
gfp
surfac
similar
vlp
vhh
direct
nondisclos
viru
also
gener
transient
express
nicotiana
benthamiana
leav
socal
tandibodi
could
use
display
antigen
vaccin
purpos
interest
see
report
technolog
vaccin
design
purpos
like
hepat
b
core
well
vhh
also
immunogen
addit
vhh
might
shield
epitop
display
antigen
due
uniqu
properti
high
solubl
stabil
eas
product
format
flexibl
vhh
seem
well
suit
develop
high
affin
reagent
fight
human
viral
diseas
current
eight
vhh
clinic
develop
compani
ablynx
one
trival
antirsv
vhh
current
test
phase
iib
clinal
trial
direct
viral
target
singledomain
buildup
allow
format
multipl
way
obtain
bestinclass
molecul
headtotail
fusion
ident
vhh
vhh
recogn
differ
epitop
fusion
multimer
protein
moieti
success
demonstr
enhanc
broaden
neutral
activ
first
strategi
exemplifi
superior
antivir
activ
strain
coverag
trival
vhh
compar
monoval
counterpart
key
compon
gener
longlast
antivir
therapeut
implement
halflif
extens
techniqu
pegyl
fusion
serum
albuminbind
vhh
fusion
igg
fcdomain
clinic
proofofconcept
extend
halflif
obtain
way
achiev
antitnf
vhh
fuse
serum
albuminbind
vhh
use
treatment
rheumatoid
arthriti
pegyl
vhh
vhh
fuse
fc
tail
yet
test
clinic
trial
fusion
fc
tail
howev
seem
promis
approach
sinc
halflif
extend
also
avid
fc
effector
function
introduc
moreov
sever
fc
fusionbas
therapeut
alreadi
market
altern
immun
effector
function
also
ad
fusion
vhh
result
recruit
tcell
next
improv
affin
extend
halflif
introduc
effector
function
format
also
improv
vhh
activ
target
certain
organ
cell
type
cell
compart
context
use
bacteri
vector
deliv
vhh
specif
organ
seem
interest
approach
explor
final
although
vhh
also
well
suit
develop
diagnost
test
still
poorli
explor
area
context
viral
infect
